The Business Magazine - B2B Business News - Site Logo

Warning: Undefined array key "tbm_visit_edition_me" in /home/970822.cloudwaysapps.com/utkbfqnuhr/public_html/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 27
The Business Magazine - B2B Business News - Site Logo
The Business Magazine July 2024
Read now
PICK YOUR EDITION

PrecisionLife to evaluate precision medicine potential of Sosei Heptares Neuroscience GPCR Target

The Business Magazine article image for: PrecisionLife to evaluate precision medicine potential of Sosei Heptares Neuroscience GPCR Target
8 November 2022

Oxfordshire-based techbio company PrecisionLife,  a pioneer in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an international biopharmaceutical group specialising in structure-based drug design targeting G protein-coupled receptors (GPCRs).

Sosei Heptares will leverage the extensive insights held in PrecisionLife’s DiseaseBank™- a repository of over 40 chronic disease studies - to determine the precision medicine opportunity of a drug targeting the nominated GPCR. The project aims to augment Sosei Heptares’ knowledge of the designated GPCR target with genetic support and prevalence insights in patients.

PrecisionLife’s studies examine differences in the chosen target, and in the biological systems on which it acts, between patients and healthy individuals. The approach taken by PrecisionLife has the potential to identify individuals who are more likely to respond to therapeutics acting on the biological target. This knowledge helps ensure that the right patients are included in future clinical trials.

Alastair Brown, Senior VP Translational Medicine, Sosei Heptares, said: “We are excited to build on our translational medicine strategy, which sees us partnering with leading-edge companies to find innovative ways to leverage our world leading discovery and early development capabilities. We look forward to working with PrecisionLife to drive our understanding of chronic disease biology and patient stratification, which is a key area of focus for Sosei Heptares.”

Dr Steve Gardner, CEO, PrecisionLife, added: “We're delighted to initiate this exciting project with Sosei Heptares, applying our unique combinatorial approach to enhance the biological validation, facilitate translation, and optimize clinical trial design in the treatment of CNS diseases. This is an area in which we share a deep commitment and complementary expertise, so we're thrilled to welcome Sosei Heptares as the newest biopharma company we're supporting to develop better, more personalized treatment options for unmet medical needs.”

Last month PrecisionLife was named Life Sciences & Health Tech Company of the Year at the 2022 Thames Valley Tech Awards during a ceremony at the Royal Berkshire Conference Centre.


Share 

Nicky Godding is editor of The Business Magazine. Before her journalism career, she worked mainly in public relations moving into writing when she was invited to launch Retail Watch, a publication covering retail and real estate across Europe.

After some years of constant travelling, she tucked away her passport and concentrated on business writing, co-founding a successful regional business magazine. She has interviewed some of the UK’s most successful entrepreneurs who have built multi-million-pound businesses and reported on many science and technology firsts.

She reports on the region’s thriving business economy from start-ups, family businesses and multi-million-pound corporations, to the professionals that support their growth and the institutions that educate the next generation of business leaders.

Latest deal ticket

All deals

Events

All events

Related news


Group Titles

Dorset BIZ NewsHampshire BIZ News
cross